Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) EBIT Margin: 2018-2025

Historic EBIT Margin for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to -558.64%.

  • Bicycle Therapeutics' EBIT Margin rose 182723.00% to -558.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 5,056.14%, marking a year-over-year increase of 828076.00%. This contributed to the annual value of -17,489.33% for FY2024, which is 1390545.00% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported EBIT Margin of -558.64% as of Q3 2025, which was up 81.16% from -2,965.82% recorded in Q2 2025.
  • Bicycle Therapeutics' EBIT Margin's 5-year high stood at 331.81% during Q4 2023, with a 5-year trough of -2,965.82% in Q2 2025.
  • Its 3-year average for EBIT Margin is -822.17%, with a median of -558.64% in 2025.
  • As far as peak fluctuations go, Bicycle Therapeutics' EBIT Margin soared by 186,954bps in 2022, and later slumped by 246,751bps in 2025.
  • Bicycle Therapeutics' EBIT Margin (Quarterly) stood at -2,253.00% in 2021, then spiked by 186,954bps to -383.46% in 2022, then surged by 71,528bps to 331.81% in 2023, then plummeted by 10,900bps to 222.82% in 2024, then skyrocketed by 182,723bps to -558.64% in 2025.
  • Its EBIT Margin was -558.64% in Q3 2025, compared to -2,965.82% in Q2 2025 and -703.66% in Q1 2025.